Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $7,566 | $5,124 | $9,032 | $12,000 |
| % Growth | 47.7% | -43.3% | -24.7% | – |
| Cost of Goods Sold | $2,740 | $746 | $725 | $472 |
| Gross Profit | $4,826 | $4,378 | $8,307 | $11,528 |
| % Margin | 63.8% | 85.4% | 92% | 96.1% |
| R&D Expenses | $11,840 | $20,295 | $12,198 | $15,929 |
| G&A Expenses | $0 | $47,302 | $17,405 | $26,979 |
| SG&A Expenses | $58,822 | $47,305 | $17,405 | $26,979 |
| Sales & Mktg Exp. | $0 | $4 | $0 | $0 |
| Other Operating Expenses | $83 | $2,537 | $0 | -$472 |
| Operating Expenses | $70,745 | $70,137 | $29,603 | $42,436 |
| Operating Income | -$65,919 | -$65,759 | -$21,296 | -$30,908 |
| % Margin | -871.3% | -1,283.4% | -235.8% | -257.6% |
| Other Income/Exp. Net | -$10,660 | -$1,236 | -$3,191 | -$4,172 |
| Pre-Tax Income | -$76,579 | -$66,995 | -$24,487 | -$35,080 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$76,579 | -$66,995 | -$24,487 | -$35,080 |
| % Margin | -1,012.1% | -1,307.5% | -271.1% | -292.3% |
| EPS | -14.78 | -14.78 | -7.17 | -12.97 |
| % Growth | 0% | -106.1% | 44.7% | – |
| EPS Diluted | -14.78 | -14.78 | -7.17 | -12.97 |
| Weighted Avg Shares Out | 5,181 | 4,534 | 3,416 | 2,704 |
| Weighted Avg Shares Out Dil | 5,181 | 4,534 | 3,416 | 2,704 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,417 | $2,740 | $476 | $123 |
| Interest Expense | $9,412 | $3,962 | $2,172 | $4,295 |
| Depreciation & Amortization | $1,269 | $836 | $718 | $472 |
| EBITDA | -$65,898 | -$62,197 | -$21,597 | -$30,313 |
| % Margin | -871% | -1,213.8% | -239.1% | -252.6% |